Rhythm Pharmaceuticals stock surges 17.1% on positive late-stage study results for setmelanotide

From Nasdaq: 2025-04-08 07:09:00

Rhythm Pharmaceuticals, Inc. (RYTM) saw a 17.1% increase in shares, closing at $54.96, following positive results from a late-stage study on setmelanotide for acquired hypothalamic obesity. The phase III TRANSCEND study showed a significant reduction in body mass index compared to a placebo, with plans for regulatory filings in the US and EU in Q3 2025.

Expectations for RYTM’s upcoming quarterly report include a projected loss of $0.67 per share and revenue of $40.82 million, up 57.2% from the previous year. Despite recent positive developments, keep an eye on earnings estimate trends as they can impact stock performance. RYTM currently holds a Zacks Rank #3 (Hold) in the Medical – Biomedical and Genetics industry.

In contrast, Phathom Pharmaceuticals, Inc. (PHAT) faced a 0.2% decline in shares, with a consensus EPS estimate of -$1.06 for the upcoming report. This represents a 25.4% increase from the prior year’s EPS, earning PHAT a Zacks Rank of #4 (Sell). Stay informed on stock performance and earnings projections as they may influence future movements.



Read more at Nasdaq: Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?